Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction

F. Reid, B. Fossland, A.D. Flapan, C.C. Duckelmann, S.A. Hudson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The objectives of this study were to validate and implement an audit tool to assess quality and appropriateness of prescribing and to compare inpatient prescribing of secondary prevention in post myocardial infarction patients before and after introduction of a local treatment guideline. The methodology involved a descriptive, non-experimental retrospective case note review comparing patients treated before and after the implementation of a clinical guideline. The analysis of Group1 patients showed that 41% required treatment with an angiotensin converting enzyme inhibitor (ACE-I), and 23% of those did not receive treatment, 20% of patients on ACE-I received sub-therapeutic doses. Seventy-two per cent of patients required treatment with a statin and 22% of those did not receive a statin. Comparison of the treatment of Group 2 showed that, of 53 patients (50% of Group 2) requiring an ACE-I, 100% received it, although 15% received sub-therapeutic doses. Of 69 patients (64% of Group 2) requiring treatment with a statin 96% were prescribed a statin. Improvements in prescribing of β-Blockers, ACE-I and statins were statistically significant. The study found that prescribing improved significantly for β-Blockers, ACE-I and statins after guideline introduction with anticipated benefits to patient outcomes.
LanguageEnglish
Pages177-178
Number of pages1
JournalPharmacy World and Science
Volume23
Issue number5
DOIs
Publication statusPublished - Oct 2001

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Secondary Prevention
Angiotensin-Converting Enzyme Inhibitors
Myocardial Infarction
Guidelines
Patient treatment
Therapeutics
Inpatients

Keywords

  • ACE inhibitors
  • aspirin
  • audit
  • betablockers
  • clinical guideline
  • myocardial infarction
  • retrospective study
  • statins

Cite this

Reid, F. ; Fossland, B. ; Flapan, A.D. ; Duckelmann, C.C. ; Hudson, S.A. / Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction. In: Pharmacy World and Science. 2001 ; Vol. 23, No. 5. pp. 177-178.
@article{778a10c8550e4b4a8ef9708a23b40c85,
title = "Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction",
abstract = "The objectives of this study were to validate and implement an audit tool to assess quality and appropriateness of prescribing and to compare inpatient prescribing of secondary prevention in post myocardial infarction patients before and after introduction of a local treatment guideline. The methodology involved a descriptive, non-experimental retrospective case note review comparing patients treated before and after the implementation of a clinical guideline. The analysis of Group1 patients showed that 41{\%} required treatment with an angiotensin converting enzyme inhibitor (ACE-I), and 23{\%} of those did not receive treatment, 20{\%} of patients on ACE-I received sub-therapeutic doses. Seventy-two per cent of patients required treatment with a statin and 22{\%} of those did not receive a statin. Comparison of the treatment of Group 2 showed that, of 53 patients (50{\%} of Group 2) requiring an ACE-I, 100{\%} received it, although 15{\%} received sub-therapeutic doses. Of 69 patients (64{\%} of Group 2) requiring treatment with a statin 96{\%} were prescribed a statin. Improvements in prescribing of β-Blockers, ACE-I and statins were statistically significant. The study found that prescribing improved significantly for β-Blockers, ACE-I and statins after guideline introduction with anticipated benefits to patient outcomes.",
keywords = "ACE inhibitors, aspirin, audit, betablockers, clinical guideline, myocardial infarction, retrospective study, statins",
author = "F. Reid and B. Fossland and A.D. Flapan and C.C. Duckelmann and S.A. Hudson",
year = "2001",
month = "10",
doi = "10.1023/A:1012231814131",
language = "English",
volume = "23",
pages = "177--178",
journal = "Pharmacy World and Science",
issn = "0928-1231",
number = "5",

}

Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction. / Reid, F.; Fossland, B.; Flapan, A.D.; Duckelmann, C.C.; Hudson, S.A.

In: Pharmacy World and Science, Vol. 23, No. 5, 10.2001, p. 177-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction

AU - Reid, F.

AU - Fossland, B.

AU - Flapan, A.D.

AU - Duckelmann, C.C.

AU - Hudson, S.A.

PY - 2001/10

Y1 - 2001/10

N2 - The objectives of this study were to validate and implement an audit tool to assess quality and appropriateness of prescribing and to compare inpatient prescribing of secondary prevention in post myocardial infarction patients before and after introduction of a local treatment guideline. The methodology involved a descriptive, non-experimental retrospective case note review comparing patients treated before and after the implementation of a clinical guideline. The analysis of Group1 patients showed that 41% required treatment with an angiotensin converting enzyme inhibitor (ACE-I), and 23% of those did not receive treatment, 20% of patients on ACE-I received sub-therapeutic doses. Seventy-two per cent of patients required treatment with a statin and 22% of those did not receive a statin. Comparison of the treatment of Group 2 showed that, of 53 patients (50% of Group 2) requiring an ACE-I, 100% received it, although 15% received sub-therapeutic doses. Of 69 patients (64% of Group 2) requiring treatment with a statin 96% were prescribed a statin. Improvements in prescribing of β-Blockers, ACE-I and statins were statistically significant. The study found that prescribing improved significantly for β-Blockers, ACE-I and statins after guideline introduction with anticipated benefits to patient outcomes.

AB - The objectives of this study were to validate and implement an audit tool to assess quality and appropriateness of prescribing and to compare inpatient prescribing of secondary prevention in post myocardial infarction patients before and after introduction of a local treatment guideline. The methodology involved a descriptive, non-experimental retrospective case note review comparing patients treated before and after the implementation of a clinical guideline. The analysis of Group1 patients showed that 41% required treatment with an angiotensin converting enzyme inhibitor (ACE-I), and 23% of those did not receive treatment, 20% of patients on ACE-I received sub-therapeutic doses. Seventy-two per cent of patients required treatment with a statin and 22% of those did not receive a statin. Comparison of the treatment of Group 2 showed that, of 53 patients (50% of Group 2) requiring an ACE-I, 100% received it, although 15% received sub-therapeutic doses. Of 69 patients (64% of Group 2) requiring treatment with a statin 96% were prescribed a statin. Improvements in prescribing of β-Blockers, ACE-I and statins were statistically significant. The study found that prescribing improved significantly for β-Blockers, ACE-I and statins after guideline introduction with anticipated benefits to patient outcomes.

KW - ACE inhibitors

KW - aspirin

KW - audit

KW - betablockers

KW - clinical guideline

KW - myocardial infarction

KW - retrospective study

KW - statins

UR - http://dx.doi.org/10.1023/A:1012231814131

U2 - 10.1023/A:1012231814131

DO - 10.1023/A:1012231814131

M3 - Article

VL - 23

SP - 177

EP - 178

JO - Pharmacy World and Science

T2 - Pharmacy World and Science

JF - Pharmacy World and Science

SN - 0928-1231

IS - 5

ER -